ClinicalTrials.gg
CompletedNCT01864005HouYiUpdated May 15, 2015Results posted

A Phase IV Study of the Onset and Maintenance of the Antiplatelet Effect of Ticagrelor Compared With Clopidogrel in Chinese Patients With ACS

A Phase 4 interventional study of Ticagrelor and Clopidogrel in Non-ST or ST Elevation Acute Coronary Syndromes, sponsored by AstraZeneca. Completed at 3 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-05-15.

Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 67 studies testing ticagrelor in Acute Coronary Syndrome — 6 open to participants now, 8 under way, 1 of them phase 3. Ticagrelor · Acute Coronary Syndrome.

Enrollment
47th of 67
60 · median 120
Started
2013
with 7 others
Phase 4
38 of 67
5 open now
Registered
14th of 67
by date
Lead sponsor
8 of 67
AstraZeneca

Among the 67 studies testing ticagrelor in Acute Coronary Syndrome, this one is the 47th largest by enrollment, is one of 8 that started in 2013, is one of 38 in phase 4, and was the 14th registered.

Acute Coronary Syndrome

1,491 studies on the registry are indexed under Acute Coronary Syndrome; 272 are open to participants now.

Browse Acute Coronary Syndrome studies →

Open to participants now

6 of the 67 studies testing ticagrelor in Acute Coronary Syndrome are open now, in 7 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About ticagrelor

Ticagrelor: first FDA approval 2011 (BRILINTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 196 Acute Coronary Syndrome studies recruiting now, 145 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies testing ticagrelor in Acute Coronary Syndrome, or all of them as a file.
02

Study summary

The purpose of this study is to test the hypothesis that the onset of the antiplatelet effect of ticagrelor is more rapid and greater than clopidogrel in Chinese patients with ACS.

03

Conditions studied

  • Non-ST or ST Elevation Acute Coronary Syndromes

Keywords

  • Non-ST or ST Elevation Acute Coronary Syndromes, Ticagrelor, Clopidogrel, Antiplatelet Effect
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Provision of prior to any study specific procedures
    1. Female or male aged at least 18 years
    1. Females of must have a negative urine pregnancy test at enrolment and be willing to use reliable
    1. Index event of non-ST or ST segment elevation ACS.

Exclusion criteria

Exclusion Criteria:

  • 1. or other reason that clopidogrel or ticagrelor should not be administered (eg, , active bleeding, moderate or severe liver disease, history of previous intracranial bleed, GI bleed within the past 6 months, major surgery within 30 days)
    1. Oral anticoagulation therapy or GP IIb/IIIa receptor antagonists therapy within 30 days prior to randomisation or cannot be stopped
    1. Ticagrelor or clopidogrel or other P2Y12 inhibitors within 14 days prior to randomisation
    1. Requires dialysis
    1. Nonselective non-steroidal anti-inflammatory drugs (NSAIDs) and prostacyclins (PGI2) therapy that cannot be stopped
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Ticagrelor

    Drug: Ticagrelor

  • Active comparator
    clopidogrel

    Drug: Clopidogrel

Interventions

  • 90mg tablets. loading dose of 180mg ticagrelor tablets (two 90mg tablets) taken orally, followed by 90mg of ticagrelor 12 hours after the first dose. Duration of treatment: 6 weeks.

  • 75mg capsule. loading dose of 600mg clopidogrel capsules (eight 75mg capsules) taken orally, follow by 75mg of clopidogrel capsules orally od. Duration of treatment: 6 weeks.

06

What researchers measure

Primary outcomes

  1. the Percentage Inhibition of the P2Y12 Receptor

    Note: the primary endpoint was changed per the statistical analysis plan prior database lock.

    Time frame: at 2 hours after first dose of study drug

Secondary outcomes

  1. the Percentage Inhibition of the P2Y12 Receptor

    Time frame: at 0.5 hour after first dose of study drug

  2. the Percentage Inhibition of the P2Y12 Receptor

    Time frame: at 8 hours after first dose of study drug

  3. the Percentage Inhibition of the P2Y12 Receptor

    Time frame: at 24 hours after first dose of study drug

  4. the Percentage Inhibition of the P2Y12 Receptor

    Time frame: at 6 weeks after first dose of study drug

07

Results

Posted Mar 2, 2015
Limitations and caveats
(1) Sample size was relatively small. (2) Study duration with 6 weeks seemed limited. (3) Sampling time-points seemed relatively scarce, such as missing the time point for 1-hour and 4-hour after loading dose.

Participant flow

First subject enrolled: 15/05/2013, Last subject last visit: 18/03/2014. There were 5 study centers in China, which participated this study.

Participant flow — Overall Study
MilestoneTicagrelorClopidogrel
Started2931
Completed2625
Not completed36
Withdrew: Protocol violation01
Withdrew: Withdrawal by subject01
Withdrew: Incorrect enrolment10
Withdrew: Disease need11
Withdrew: Need gp iib/iiia13

Outcome measures

Primarythe Percentage Inhibition of the P2Y12 Receptor

Note: the primary endpoint was changed per the statistical analysis plan prior database lock.

Time frame:
at 2 hours after first dose of study drug
Reported as:
Mean · Percentage Inhibition
the Percentage Inhibition of the P2Y12 Receptor
Percentage InhibitionTicagrelorClopidogrel
the Percentage Inhibition of the P2Y12 Receptor48.20 ± 45.4109.78 ± 27.574
Statistical analysis
  • Ticagrelor vs Clopidogrel · Wilcoxon (Mann-Whitney) · p = 0.0021 (not adjusted for multiple comparisons. statistical significance level: 0.05)
  • Ticagrelor vs Clopidogrel · ANOVA · p = 0.0003 · Mean difference (final values): 38.421 · 95% CI 18.559 to 58.283
Secondarythe Percentage Inhibition of the P2Y12 Receptor
Time frame:
at 0.5 hour after first dose of study drug
Reported as:
Mean · Percentage Inhibition
the Percentage Inhibition of the P2Y12 Receptor
Percentage InhibitionTicagrelorClopidogrel
the Percentage Inhibition of the P2Y12 Receptor8.23 ± 25.810-3.91 ± 13.602
Statistical analysis
  • Ticagrelor vs Clopidogrel · Wilcoxon (Mann-Whitney) · p = 0.0828
Secondarythe Percentage Inhibition of the P2Y12 Receptor
Time frame:
at 8 hours after first dose of study drug
Reported as:
Mean · Percentage Inhibition
the Percentage Inhibition of the P2Y12 Receptor
Percentage InhibitionTicagrelorClopidogrel
the Percentage Inhibition of the P2Y12 Receptor67.91 ± 34.85625.38 ± 32.738
Statistical analysis
  • Ticagrelor vs Clopidogrel · Wilcoxon (Mann-Whitney) · p = <0.0001
Secondarythe Percentage Inhibition of the P2Y12 Receptor
Time frame:
at 24 hours after first dose of study drug
Reported as:
Mean · Percentage Inhibition
the Percentage Inhibition of the P2Y12 Receptor
Percentage InhibitionTicagrelorClopidogrel
the Percentage Inhibition of the P2Y12 Receptor79.25 ± 17.92028.76 ± 26.917
Statistical analysis
  • Ticagrelor vs Clopidogrel · Wilcoxon (Mann-Whitney) · p = <0.0001
Secondarythe Percentage Inhibition of the P2Y12 Receptor
Time frame:
at 6 weeks after first dose of study drug
Reported as:
Mean · Percentage Inhibition
the Percentage Inhibition of the P2Y12 Receptor
Percentage InhibitionTicagrelorClopidogrel
the Percentage Inhibition of the P2Y12 Receptor83.78 ± 13.94724.22 ± 33.546
Statistical analysis
  • Ticagrelor vs Clopidogrel · Wilcoxon (Mann-Whitney) · p = <0.0001

Adverse events

Collected over 6 weeks for all AEs and another 14 days for SAEs.. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ticagrelor—1/29 (3.4%)12/29 (41.4%)
Clopidogrel—1/31 (3.2%)12/31 (38.7%)
Most frequent serious events
Most frequent serious events
EventTicagrelorClopidogrel
Upper gastrointestinal haemorrhageGastrointestinal disorders1/290/31
Drug-induced liver injuryInjury, poisoning and procedural complications0/291/31
Most frequent other events
Showing 10 of 33
Most frequent other events
EventTicagrelorClopidogrel
Hypertensive heart diseaseCardiac disorders3/292/31
HyperuricaemiaMetabolism and nutrition disorders3/292/31
Hepatic function abnormalHepatobiliary disorders2/293/31
HyperlipidaemiaMetabolism and nutrition disorders2/291/31
Type 2 diabetes mellitusMetabolism and nutrition disorders2/290/31
Back painMusculoskeletal and connective tissue disorders2/290/31
ArrhythmiaCardiac disorders0/292/31
Lung infectionInfections and infestations1/290/31
PharyngitisInfections and infestations1/290/31
Upper respiratory tract infectionInfections and infestations1/290/31

Baseline characteristics

Three randomized patients were excluded from the full analysis set (FAS) due to any of the following reasons: 1) did not meet exclusion requirments but was randomized, 2)post-treatment blood PRU was not available, 3) pre-treatment blood PRU was missing, and 4) use of prohibited medications.

Age, Continuous
Age, Continuous(years)TicagrelorClopidogrelTotal
Mean58.75 ± 10.96758.59 ± 9.78958.67 ± 10.291
Sex: Female, Male
Sex: Female, Male(Participants)TicagrelorClopidogrelTotal
Female2810
Male262147
Race (NIH/OMB)
Race (NIH/OMB)(Participants)TicagrelorClopidogrelTotal
American Indian or Alaska Native000
Asian282957
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
08

Study locations

3 sites
  • Research Site
    Beijing, China
  • Research Site
    Shenyang, China
  • Research Site
    Tianjin, China
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2013, a primary completion of Mar 2014 and a completion of Mar 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2015, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2013
First posted
May 29, 2013
Start
May 2013
Primary completionActual
Mar 2014
CompletionActual
Mar 2014
Results first posted
Mar 2, 2015
Last update
May 15, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01864005
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
May 29, 2013
Start date
May 2013
Primary completion
Mar 2014
Completion
Mar 2014
Results posted
Mar 2, 2015
Last update
May 15, 2015

Study contacts

Yundai Chen, Professor
principal investigator · The General Hospital of People's Liberation Army

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ticagrelor

Start the discussion